Aptamer-guided delivery of miR-126 suppresses glioblastoma stem-like cell invasion and tumor progression.

Aptamer-guided delivery of miR-126 significantly reduces glioblastoma stem-like cell invasion and tumor progression in mouse models.

• Why it matters: Glioblastoma has a median survival of 15-18 months, and new targeted therapies are urgently needed to improve patient outcomes. miRNAs like miR-126 may serve as promising therapeutic targets due to their regulatory roles.
• What they did: Researchers restored miR-126 expression in GBM stem-like cells via transduction and delivered it through an aptamer-based conjugate, then evaluated effects in GBM mouse models.
• The result: Systemic treatment with the aptamer-miR-126 chimera markedly decreased brain infiltration, supporting miR-126’s role as a tumor suppressor and its potential as a targeted therapy for GBM.